RESOLVING THE LEDGER
RESOLVING THE LEDGER
Only one outlet has reported this event so far — you're reading it below, credited to its source. AIPROPX is tracking the web for more coverage; as additional outlets confirm it, this becomes a full multi-source story automatically.
By AIPROPX Editorial Desk · Published · Updated
One outlet is reporting this so far. AIPROPX is tracking it and will gather every additional source as it develops — the full multi-source comparison appears automatically once a second outlet confirms it.
Greg Verdine is having a very good year.
The scientist-turned-biotech entrepreneur has been basking in the knowledge that the science he had tried to propel forward nearly 15 years ago may have changed the landscape for pancreatic cancer patients .
His more recent ventures are taking off. One, Parabilis Medicines, went public in June in one of the industry’s largest IPOs in recent years. The other, LifeMine, has raised $263 million, it announced Thursday, enough to advance a drug that Verdine believes could make organ transplants more viable and potentially help people with autoimmune conditions.
Continue to STAT+ to read the full story…
Indexed and credited by AIPROPX. Originating outlet: STAT. Open at source →
An original, deterministic readout — composed only from the computed coverage facts on this page. No interpretation, no rating; figures only.
AIPROPX has consolidated 1 report from 1 outlet into a single canonical entry on “STAT+: A scientist-turned-biotech executive is notching some wins, and enjoying it.” Every covered outlet is based in Other.
The only timestamped report came from STAT (Aug 6, 2026, 10:30 UTC).
Comparing the wording across sources, the phrase recurring most across the coverage is “scientist turned biotech executive”.
2 statements are carried by only one outlet within this set and are not echoed by the others.
Every figure above is a direct count of real published articles. AIPROPX indexes and compares the original reporting — it never rewrites, rates, or editorializes — and each publisher’s full article is always one click away.
Generated by AIPROPX from the source counts above. AIPROPX indexes and resolves coverage; the original publishers are credited and linked at origin in every report.
Coverage from 1 independent outlet across 1 region — each view opens on its own page.
AIPROPX — “STAT+: A scientist-turned-biotech executive is notching some wins, and enjoying it” · https://www.aipropx.com/story/766566b33845e727ef866ab6045f666d
Other events being covered across multiple sources right now.
NASA scientist: SpaceX rocket stage moon impact poses no risk
4 outletsTasic wins Passaic Democratic nomination for county commissioner
3 outletsTrump denies U.S. running low on some munitions, says vast resupplies being made
3 outletsWhy some parents and teachers want the president of Seattle's teachers union to step down
3 outletsVollering wins stage five as Reusser retains yellow
1 outletsBiotech’s next big bet: A Tenax study of a heart failure treatment